Update on Endocrine-related Tumors

Key words

endocrine-related tumors - adrenal - peptide analogues - international symposium Dresden

References

• 1 Mansmann G, Lau J, Balk E, Rothberg M, Miyachi Y, Bornstein SR. The clinically inapparent adrenal mass: update in diagnosis and management.  Endocr Rev. 2004;  25 309-340
• 2 Stratakis CA, Marx SJ. Multiple endocrine neoplasias in the era of translational medicine.  Horm Metab Res. 2005;  37 343-346
• 3 Stratakis CA. Adrenocortical tumors, primary pigmented adrenocortical disease (PPNAD)/Carney complex, and other bilateral hyperplasias: the NIH studies.  Horm Metab Res. 2007;  39 467-473
• 4 Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.  S. adults. N Engl J Med. 2003;  348 1625-1638
• 5 Engel JB, Schally AV. Drug Insight: clinical use of agonists and antagonists of luteinizing-hormone-releasing hormone.  Nat Clin Pract Endocrinol Metab. 2007;  3 157-167
• 6 Schally AV, Nagy A. Chemotherapy targeted to cancers through tumoral hormone receptors.  Trends Endocrinol Metab. 2004;  15 300-310
• 7 Schally AV. New approaches to the therapy of various tumors based on peptide analogues.  Horm Metab Res. 2008;  40 315-322
• 8 Engel JB, Schally AV, Dietl J, Rieger L, Honig A. Targeted therapy of breast and gynecological cancers with cytotoxic analogues of peptide hormones.  Mol Pharm. 2007;  4 652-658
• 9 Buchholz S, Keller G, Schally AV. et al . Therapy of ovarian cancers with targeted cytotoxic analogs of bombesin, somatostatin, and luteinizing hormone-releasing hormone and their combinations.  Proc Natl Acad Sci USA. 2006;  103 10403-10407
• 10 Eisenhofer G, Siegert G, Kotzerke J, Bornstein SR, Pacak K. Current progress and future challenges in the biochemical diagnosis and treatment of phaeochromocytomas and paragangliomas.  Horm Metab Res. 2008;  40 329-337
• 11 Pacak K, Eisenhofer G. An assessment of biochemical tests for the diagnosis of pheochromocytoma.  Nat Clin Pract Endocrinol Metab. 2007;  3 744-745
• 12 Lenders JW, Eisenhofer G, Mannelli M, Pacak K. Phaeochromocytoma.  Lancet. 2005;  366 665-675
• 13 Lenders JW, Eisenhofer G, Mannelli M, Pacak K. Phaeochromocytoma.  Lancet. 2005;  366 665-675
• 14 Pacak K, Eisenhofer G, Ahlman H. et al . Pheochromocytoma: recommendations for clinical practice from the First International Symposium. October 2005.  Nat Clin Pract Endocrinol Metab. 2007;  3 92-102
• 15 Benvenga S. Update on thyroid cancer.  Horm Metab Res. 2008;  40 323-328
• 16 Montoya M, Brown JW, Fishman LM. Comparative effects of chemotherapeutic agents on the growth and survival of human adrenal carcinoma cells in culture.  Horm Metab Res. 2008;  40 302-305
• 17 Brown JW, Prieto LM, Perez-Stable C, Montoya M, Cappell S, Fishman LM. Estrogen and progesterone lower cyclin B1 and D1 expression, block cell cycle in G2/M, and trigger apoptosis in human adrenal carcinoma cell cultures.  Horm Metab Res. 2008;  40 306-310
• 18 Prieto LM, Brown JW, Perez-Stable C, Fishman LM. High dose 17β-estradiol and the α-estrogen agonist PPT trigger apoptosis in human adrenal carcinoma cells but the β-estrogen agonist DPN does not.  Horm Metab Res. 2008;  40 311-314
• 19 Kasperlik-Zaluska AA, Otto M, Cichocki A. et al . Incidentally discovered adrenal tumors: a lesson from observation of 1444 patients.  Horm Metab Res. 2008;  40 338-341
• 20 Grumbach MM, Biller BM, Braunstein GD. et al . Management of the clinically inapparent adrenal mass (“incidentaloma”).  Ann Intern Med. 2003;  138 424-429
• 21 Bornstein SR, Stratakis CA, Chrousos GP. Adrenocortical tumors: recent advances in basic concepts and clinical management.  Ann Intern Med. 1999;  130 759-771
• 22 Johansson T, Lejonklou MH, Ekeblad S, Stålberg P, Skogseid B. Lack of nuclear expression of hairy enhancer of split-1 (HES1) in pancreatic endocrine tumors.  Horm Metab Res. 2008;  40 354-359
• 23 Ziegler CG, Sicard F, Lattke P, Bornstein SR, Ehrhart-Bornstein M, Krug AW. Dehydroepiandrosterone (DHEA) induces a neuroendocrine phenotype in nerve growth factor (NGF)-stimulated chromaffin pheochromocytoma PC12 cells.  Endocrinology. 2008;  149 320-328
• 24 Sicard F, Ehrhart-Bornstein M, Corbeil D. et al . Age-dependent regulation of chromaffin cell proliferation by growth factors, dehydroepiandrosterone (DHEA), and DHEA sulfate.  Proc Natl Acad Sci USA. 2007;  104 2007-2012
• 25 Schwarz PE, Reimann M, Li J. et al . The metabolic syndrome - a global challenge for prevention.  Horm Metab Res. 2007;  39 777-780
• 26 Boikos SA, Horvath A, Heyerdahl S. et al . Phosphodiesterase 11A expression in the adrenal cortex, primary pigmented nodular adrenocortical disease, and other corticotropin-independent lesions.  Horm Metab Res. 2008;  40 347-353

Correspondence